March 4 (Reuters) - Genetic Technologies Ltd (GTG) :
- GENETIC TECHNOLOGIES SIGNS MULTI-YEAR US DISTRIBUTION AGREEMENT FOR COVID RISK TEST
- GENETIC TECHNOLOGIES LTD - CO SIGNS CO-EXCLUSIVE PRODUCTION AND DISTRIBUTION RIGHTS AND LICENSE AGREEMENT WITH INFINITY BIOLOGIX LLC
- GENETIC TECHNOLOGIES LTD - IBX IS REQUIRED TO MAKE MINIMUM PAYMENTS TO CO TOTALING US$2.9 MILLION OVER TERM TO MAINTAIN EXCLUSIVITY
- GENETIC TECHNOLOGIES LTD - UNDERLYING ROYALTY STRUCTURE IS ON A PER UNIT BASIS OF US$10
- GENETIC TECHNOLOGIES LTD - IBX WILL DEFINE AND DECIDE SALES AND END-TO-CONSUMER PRICING STRUCTURE FOR COVID-19 RISK TEST
- GENETIC TECHNOLOGIES LTD - GTG TEAM IS IN FINAL STAGES TO SUBMIT COVID-19 RISK TEST FOR CLEARANCE FROM CLINICAL LABORATORY IMPROVEMENT AMENDMENTS
News: GTG Genetic Technologies Signs Multi-Year US Distribution Agreement For COVID Risk Test
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
